5 / 23
Page 51
allied
academies
J Med Oncl Ther 2017 | Volume 2 Issue 4
Oncology and Biomarkers Summit
November 27-28, 2017 | Atlanta, USA
Annual Congress on
B
reast cancer is one of the leading cause of death
worldwide. In Pakistan, prevalence of this ailment is
highest amongst all types of cancer i.e. 38.5%. Among various
treatments available to overcome cancer, chemotherapy is
the one used most widely most oftenly a combination of two
or more medicines will be used as chemotherapy treatment
for breast cancer. But in Chemotherapy, major clinical
setback is drug resistance. Metabolomics is an emerging
field that utilizes information of cellular biochemistry
for the early detection, diagnosis and establishment of
predictive biomarkers of breast cancer. Currently, metabolics
is use to evaluate a much comprehensive picture of tumor
development and growth This review highlights potential
metabolomics applications towards developing a more
personalized and tailored chemotherapy treatment. The
methodology is based on inclusion exclusion criteria.
Literature survey and questionnaire were included while
clinical trials was excluded. This report provides a review
of 12 articles out which few were excluded. The objective
was to explore: Early breast cancer detection; Increasing
life expectancy of cancer patients; Mechanisms for breast
cancer drug resistance; Chemotherapy in breast cancer and
its success rate and Side effects of chemotherapy in breast
cancer. According to the survey the average response rate of
a cancer drug is the lowest at 21%, suggesting that 79% of
patients with cancer are over-dosed. While according to an
international study, 40%–50% of breast tumors will display
acquired resistance. When specific therapies are chosen on
the basis of a patient’s metabolomics profile, it will give rise
to customized medicine and personalized tailored treatment.
Using high throughput information using metabolomics
to clinical diagnosis and treatment can help accelerate the
patient safety, quality of life and survival rate by identifying
pathways involved in drug resistance. Metabolomics is future
of anti-cancer pharmacology, following “the right drug for
the right patient at the right time” can offer safety, quality
and effectiveness of anti-cancer treatment.
e:
mahi.umber@gmail.comInnovative approaches in metabolomics for understanding drug resistance in breast cancer
Umber Saeed
Dow University Of Health and Sciences, Pakistan